The following research publications were supported by the Centre:


1 Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Steele NG, Biffi G, Kemp SB, Zhang Y, Drouillard D, Syu L, Hao Y, Oni TE, Brosnan E, Elyada E, Doshi A, Hansma C, Espinoza C, Abbas A, The S, Irizarry-Negron V, Halbrook CJ, Franks NE, Hoffman MT, Brown K, Carpenter ES, Nwosu ZC, Johnson C, Lima F, Anderson MA, Park Y, Crawford HC, Lyssiotis CA, Frankel TL, Rao A, Bednar F, Dlugosz AA, Preall JB, Tuveson DA, Allen BL and di Magliano MP.
Clin Cancer Res. Apr 2021; doi: 10.1158/1078-0432.CCR-20-3715

2 CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function
Whiteside SK, Grant FM, Gyori DS, Conti AG, Imianowski CJ, Kuo P, Nasrallah R, Sadiyah F, Lira SA, Tacke F, Eil RL, Burton OT, Dooley J, Liston A, Okkenhaug K, Yang J, Roychoudhuri R.
Immunology. Apr 2021; doi: 10.1111/imm.13337

3 Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN, Goulart MR, Hughes C, Imrali A, Roberts R, Pawula M, Houghton R, Lawrence C, Yogeswaran K, Mousa K, Coetzee C, Sasieni P, Prendergast A and David Propper.
Nat Commun. Oct 2020; doi: 10.1038/s41467-020-18636-w

4 Diversity and Biology of Cancer-associated Fibroblasts
Biffi G. and Tuveson DA.
Physiol. Rev. Oct 2020 doi:10.1152/physrev.00048.2019

5 CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci, Martin Smoragiewicz, Claire M. Connell, Zhikai Wang, Ya Gao, James E. D. Thaventhiran, Bristi Basu, Lukasz Magiera, T. Isaac Johnson, Lisa Bax, Aarthi Gopinathan, Christopher Isherwood, A. Gallagher, Maria Pawula, Irena Hudecova, Davina Gale, Nitzan Rosenfeld, Petros Barmpounakis, Elizabeta Cristina Popa, Rebecca Brais, Edmund Godfrey, Fraz Mir, Frances M. Richards, Douglas T. Fearon, Tobias Janowitz, and Duncan I. Jodrell.
PNAS 2020, October 30. DOI: 10.1073/pnas.2013644117

6 Magnetic resonance fingerprinting of the pancreas at 1.5 T and 3.0 T
Serrao EM, Kessler DA, Carmo B, Beer L, Brindle KM, Buonincontri G, Gallagher FA, Gilbert FJ, Godfrey E, Graves MJ, McLean MA, Sala E, Schulte RF, Kaggie JD.
Sci Rep. 2020 Oct 16;10(1):17563. doi: 10.1038/s41598-020-74462-6.

7 Tracing the origin of pancreatic cancer fibroblast heterogeneity
Biffi G.
CMGH. Jul 2020; doi: 10.1016/j.jcmgh.2020.06.008

8 SOAT1 promotes mevalonate pathway dependency in pancreatic cancer
Oni TE, Biffi G, Baker LA, Hao Y, Tonelli C, Somerville TDD, Deschênes A, Belleau P, Hwang CI, Sánchez-Rivera FJ, Cox H, Brosnan E, Doshi A, Lumia RP, Khaledi K, Park Y, Trotman LC, Lowe SW, Krasnitz A, Vakoc CR and Tuveson DA.
J Exp Med. Jul 2020; doi: 10.1084/jem.20192389

9 Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
Corrie PG, Qian W, Basu B, Valle JW, Falk S, Iwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J, Arif S, Bridgewater J, Propper D, Gillmore R, Gopinathan A, Skells R, Bundi B, Brais R, Dalchau K, Bax L, Chhabra A, Machin A, Dayim A, McAdams K, Cummins S, Wall L, Ellis R, Anthoney A, Evans J, Ma YT, Isherwood C, Neesse A, Tuveson D and Jodrell DI.
Br. J. Cancer. Apr 2020; doi: 10.1038/s41416-020-0846-2

10 MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Sodir NM, Kortlever RM, Barthet VJA, Campos T, Pellegrinet L, Kupczak S, Anastasiou P, Swigart LB, Soucek L, Arends MJ, Littlewood TD, Evan GI.
Cancer Discov. 2020 Apr;10(4):588-607. doi: 10.1158/2159-8290.CD-19-0435. Epub 2020 Jan 15.

11 Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, Hwang C, Öhlund D, Chio IIC, Baker LA, Filippini D, Wright K, Bapiro TE, Huang P, Smith P, Yu KH, Jodrell DI, Park Y and Tuveson DA.
Clin Cancer Res. Nov 2019; doi: 10.1158/1078-0432.CCR-19-1398

12 SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer
Ramu I, Buchholz SM, Patzak MS, Goetze RG, Singh SK, Richards FM, Jodrell DI, Sipos B, Ströbel P, Ellenrieder V, Hessmann E and Neesse A.
EBioMedicine. Oct 2019; doi: 10.1016/j.ebiom.2019.09.024

13 The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.
Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI.
Mol Cancer Ther. 2018 Aug;17(8):1670-1682. doi: 10.1158/1535-7163.MCT-18-0010. Epub 2018 Jun 11.

14 Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI.
Cancer Res. 2018 Jun 1;78(11):3054-3066. doi: 10.1158/0008-5472.CAN-17-3932. Epub 2018 May 7.

15 CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype
Candido JB, Morton, JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR and Sansom OJ.
Cell Rep. May 2018; doi: 10.1016/j.celrep.2018.03.131

16 A case of lymphangioma-like mesenteric cysts diagnosed as adenocarcinoma of possible pancreatic origin on EUS-FNA.
Delvincourt M, Godfrey EM, Duckworth A, Carroll NR.
Gastrointest Endosc. 2018 May;87(5):1359-1361. doi: 10.1016/j.gie.2017.10.036. Epub 2017 Nov 4. No abstract available.

17 Multicenter experience from the UK and Ireland of use of lumen-apposing metal stent for transluminal drainage of pancreatic fluid collections.
Venkatachalapathy SV, Bekkali N, Pereira S, Johnson G, Oppong K, Nayar M, Leeds J, Paranandi B, Penman I, Carroll N, Godfrey E, James M, Aithal G, McKay C, Devlin J, Wong T, Makin A, Ryan B, Huggett M.
Endosc Int Open. 2018 Mar;6(3):E259-E265. doi: 10.1055/s-0043-125362. Epub 2018 Feb 28.

18 A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D.
Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13.

19 Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.
Feretis M, Wang T, Iype S, Duckworth A, Brais R, Basu B, Jamieson NV, Huguet E, Balakrishnan A, Jah A, Praseedom RK, Harper SJ, Liau SS.
Pancreas. 2017 Nov/Dec;46(10):1314-1321. doi: 10.1097/MPA.0000000000000929.

20 Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
Narvaez AJ, Ber S, Crooks A, Emery A, Hardwick B, Guarino Almeida E, Huggins DJ, Perera D, Roberts-Thomson M, Azzarelli R, Hood FE, Prior IA, Walker DW, Boyce R, Boyle RG, Barker SP, Torrance CJ, McKenzie GJ, Venkitaraman AR.
Cell Chem Biol. 2017 Aug 17;24(8):1017-1028.e7. doi: 10.1016/j.chembiol.2017.07.009. Epub 2017 Aug 10.

21 Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis.
Sivakumar S, de Santiago I, Chlon L, Markowetz F.
PLoS Med. 2017 Jan 31;14(1):e1002223. doi: 10.1371/journal.pmed.1002223. eCollection 2017 Jan.

22 Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.
Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.
Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010.
23 Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.
Perera D, Venkitaraman AR.
Sci Rep. 2016 Jul 14;6:29741. doi: 10.1038/srep29741.

24 CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. 
Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI.
Cancer Res. 2015 Sep 1;75(17):3583-95. doi: 10.1158/0008-5472.CAN-14-3347. Epub 2015 Jul 3.

25 First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U.
Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422. Epub 2015 Mar 24.

26 Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma.
Cook N, Brais R, Qian W, Hak CC, Corrie PG.
J Clin Pathol. 2015 Apr;68(4):309-13. doi: 10.1136/jclinpath-2014-202521. Epub 2015 Jan 8.

27 Negative predictive value of drain amylase concentration for development of pancreatic fistula after pancreaticoduodenectomy.
Zelga P, Ali JM, Brais R, Harper SJ, Liau SS, Huguet EL, Jamieson NV, Praseedom RK, Jah A.
Pancreatology. 2015 Mar-Apr;15(2):179-84. doi: 10.1016/j.pan.2014.12.003. Epub 2014 Dec 30.

28 Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Elias A, Chatzizacharias NA, Xanthis A, Corrie P, Davies S, Brais RJ, Jamieson NV, Praseedom RK, Huguet E, Harper SJ, Jah A.
Medicine (Baltimore). 2015 Feb;94(6):e499. doi: 10.1097/MD.0000000000000499.